The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Boehler Life Science Advice; BPGbio; ClearNote Health; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient; TD2; Vivacitus
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
Gayle S. Jameson
No Relationships to Disclose
 
Courtney Edwards Snyder
No Relationships to Disclose
 
Amar Thosani
No Relationships to Disclose
 
Steven Sckolnik
No Relationships to Disclose
 
Ronald Lee Korn
No Relationships to Disclose
 
Syed Rahmanuddin
No Relationships to Disclose
 
Dan Mocan
No Relationships to Disclose
 
Shelby Pearse
No Relationships to Disclose
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics; Viracta Therapeutics
Research Funding - AADi (Inst); Abbvie (Inst); Advaxis (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BioEclipse Therapeutics (Inst); BiolineRx (Inst); BiolineRx (Inst); BioNTech (Inst); BioXCel therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Codiak Biosciences (Inst); Coordination Therapeutics (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); Dracen (Inst); Driver Group (Inst); DynamiCure Biotechnology (Inst); Elevation Oncology (Inst); Endocyte (Inst); Faeth Therapeutics (Inst); FibroGen (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HCW Biologics (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); HiberCell (Inst); I-Mab (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); InhibRx (Inst); Inhibrx (Inst); Intra ImmuSG (Inst); Istari Oncology (Inst); Jubilant Therapeutics (Inst); Lilly/ImClone (Inst); MabVax (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoResponse (Inst); PEEL Therapeutics (Inst); Pfizer (Inst); Pionyr (Inst); Pionyr (Inst); Plexxikon (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Riboscience (Inst); Rubius Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Sirnaomics (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trishula Therapeutics (Inst); TTC Oncology (Inst); TTC Oncology (Inst); Vedanta Biosciences (Inst); Veru (Inst); Y-mAbs Therapeutics (Inst); Zai Lab (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - AADi; Anthem Inc; CerRx; FORMA Therapeutics; Medtronic; Origin Commercial Advisors; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - Agastiya Biotech; Agenus; AiMed; AlaMab Therapeutics; Alpha Cancer Technologies; Aptose Biosciences; Athenex; Avesta76 Therapeutics; Axis Therapeutics; Bessor Pharma; BioXCel therapeutics; Bristol Myers Squibb; Bryologyx; CanBas; Caribou Biosciences; Catamaran Bio; Codiak Biosciences; Compass Therapeutics; Coordination Pharmaceuticals; Corcept Therapeutics; Cytocom; Decoy Biosystems; EMD Serono; Erimos Pharmaceuticals; EXACT Therapeutics; Geistlich Pharma; Genzada Pharmaceuticals; GiraFpharma; GlaxoSmithKline; HUYA Bioscience International; ImaginAb; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; Invios GmbH; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Lycia Therapeutics; Mekanistic Therapeutics; NeoTx; NGM Biopharmaceuticals; Nirogy Therapeutics; Novita Pharmaceuticals; Noxxon Pharma; Oncology Venture; OnQuality Pharmaceuticals; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; POINT Biopharma; Red Arrow Therapeutics; Reglagene; Remix Therapeutics; RenovoRx; Samumed; Seagen; Sellas Life Sciences; Senhwa Biosciences; SignaBlok; Sirnaomics; SMP Oncology fka SDP/Tolero; Soley Therapeutics; SonaCare Medical; SOTIO; TD2; Thirona Biosciences; Verily; Vicus Therapeutics; Viracta Therapeutics; Vivacitas Oncology; Xenter; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Aryan Modasi
No Relationships to Disclose
 
Albert Amini
No Relationships to Disclose